SEER-1: phase 3 RGN-259 ophthalmic solution for neurotrophic keratopathy
Neurotrophic Keratopathy
Enrolment: 18 · Results not recorded
Loading the evidence…
Biologic · No ChEMBL mechanism record retrieved. Parent entity CHEMBL4594313 TIMBETASIN (Protein, max_phase 2); the acetate salt CHEMBL4594314 carries max_phase 3. Related INN glemtimbetasin CHEMBL6068252 (max_phase 2).
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Neurotrophic Keratopathy
Enrolment: 18 · Results not recorded
Neurotrophic Keratopathy
Enrolment: 70 · Results not recorded
Venous Stasis Ulcers
Enrolment: 72 · Results not recorded
Pressure Ulcers
Enrolment: 72 · Results not recorded
Epidermolysis Bullosa
Enrolment: 30 · Results not recorded
Diabetes
Enrolment: 12 · Results not recorded
Dry Eye Syndrome
Enrolment: 72 · Results not recorded
Acute Myocardial Infarction
Enrolment: 90 · Results not recorded
Acute Myocardial Infarction · STEMI
Enrolment: 0 · Results not recorded
Atherosclerotic Cardiovascular Disease · Endothelial Dysfunction
Enrolment: 80 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Infrarenal abdominal aorta cross-clamping with an atraumatic microvascular clamp for 90 min of ischaemia followed by 180 min of reperfusion, under pentobarbital sodium anaesthesia (60 mg/kg intraperitoneal) with midline laparotomy and heparin 50 U/kg intravenously before ischaemia
Thymosin beta 4 given either before ischaemia or before reperfusion reduced the lung wet to dry ratio (3.94 +/- 0.32 and 3.42 +/- 0.29 versus 5.44 +/- 0.27 for untreated ischaemia-reperfusion), lowered lipid hydroperoxide, malondialdehyde, pro-oxidant/antioxidant balance and pro-inflammatory cytoki…
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.92. Machine-extracted fields require source verification.